Cyclacel Total Current Assets vs Retained Earnings Analysis

CYCC Stock

USD 1.51 0.09 5.63%

Cyclacel Pharmaceuticals financial indicator trend analysis is way more than just evaluating Cyclacel Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclacel Pharmaceuticals is a good investment. Please check the relationship between Cyclacel Pharmaceuticals Total Current Assets and its Retained Earnings accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.

Total Current Assets vs Retained Earnings

Total Current Assets vs Retained Earnings Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclacel Pharmaceuticals Total Current Assets account and Retained Earnings. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Cyclacel Pharmaceuticals' Total Current Assets and Retained Earnings is -0.04. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Cyclacel Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Cyclacel Pharmaceuticals' Total Current Assets and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Cyclacel Pharmaceuticals are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Total Current Assets i.e., Cyclacel Pharmaceuticals' Total Current Assets and Retained Earnings go up and down completely randomly.

Correlation Coefficient

-0.04

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most indicators from Cyclacel Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclacel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.At present, Cyclacel Pharmaceuticals' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.04, whereas Selling General Administrative is forecasted to decline to about 5.9 M.

	2023	2024 (projected)
Discontinued Operations	17.1K	30.4K
Cost Of Revenue	31K	29.5K

Discontinued Operations Cost Of Revenue

Cyclacel Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.57	0.23	0.15	-0.34	0.01	0.02	0.14	-0.06	0.0	0.18	-0.31	-0.69	-0.32	0.83	0.09	-0.02	0.94	0.09	0.09	0.12	-0.04	0.0	0.93	0.11	0.09
Total Stockholder Equity	0.57		-0.53	-0.72	-0.03	0.72	-0.8	-0.69	0.21	-0.69	-0.52	0.55	-0.98	0.02	0.92	-0.58	-0.37	0.79	0.27	-0.3	-0.73	-0.1	-0.63	0.82	-0.74	0.02
Retained Earnings	0.23	-0.53		0.83	-0.67	-0.93	0.8	0.91	-0.2	0.72	0.69	-0.9	0.37	-0.4	-0.19	0.37	0.04	0.05	0.13	0.61	0.84	-0.21	0.6	-0.04	0.85	-0.24
Other Assets	0.15	-0.72	0.83		-0.24	-0.85	0.97	0.97	-0.42	0.77	0.82	-0.95	0.6	-0.36	-0.41	0.78	0.38	-0.15	-0.27	0.43	1.0	0.03	0.8	-0.21	0.99	0.02
Common Stock Shares Outstanding	-0.34	-0.03	-0.67	-0.24		0.45	-0.16	-0.42	-0.02	-0.19	-0.42	0.48	0.14	0.47	-0.25	0.16	0.51	-0.36	-0.44	-0.37	-0.27	0.34	-0.23	-0.28	-0.28	0.29
Other Stockholder Equity	0.01	0.72	-0.93	-0.85	0.45		-0.88	-0.9	0.21	-0.76	-0.68	0.82	-0.59	0.35	0.44	-0.47	-0.17	0.21	-0.02	-0.57	-0.86	0.14	-0.68	0.3	-0.87	0.22
Total Liab	0.02	-0.8	0.8	0.97	-0.16	-0.88		0.93	-0.3	0.84	0.75	-0.87	0.69	-0.26	-0.53	0.79	0.46	-0.28	-0.28	0.42	0.97	0.09	0.78	-0.33	0.97	0.04
Short Long Term Debt Total	0.14	-0.69	0.91	0.97	-0.42	-0.9	0.93		-0.45	0.72	0.85	-0.97	0.57	-0.43	-0.38	0.62	0.16	-0.12	-0.16	0.47	0.98	-0.14	0.8	-0.2	0.98	-0.15
Other Current Liab	-0.06	0.21	-0.2	-0.42	-0.02	0.21	-0.3	-0.45		0.22	-0.58	0.44	-0.25	0.57	0.14	-0.3	0.25	0.02	0.27	-0.05	-0.44	0.36	-0.56	0.1	-0.44	0.22
Total Current Liabilities	0.0	-0.69	0.72	0.77	-0.19	-0.76	0.84	0.72	0.22		0.41	-0.68	0.56	0.17	-0.44	0.57	0.58	-0.26	-0.13	0.39	0.76	0.21	0.43	-0.27	0.76	0.09
Property Plant And Equipment Net	0.18	-0.52	0.69	0.82	-0.42	-0.68	0.75	0.85	-0.58	0.41		-0.83	0.46	-0.69	-0.27	0.69	-0.09	-0.05	-0.21	0.32	0.84	-0.14	0.96	-0.13	0.83	-0.11
Current Deferred Revenue	-0.31	0.55	-0.9	-0.95	0.48	0.82	-0.87	-0.97	0.44	-0.68	-0.83		-0.41	0.46	0.21	-0.62	-0.18	-0.06	0.14	-0.45	-0.95	0.07	-0.72	0.02	-0.95	0.03
Net Debt	-0.69	-0.98	0.37	0.6	0.14	-0.59	0.69	0.57	-0.25	0.56	0.46	-0.41		0.02	-0.97	0.54	0.32	-0.88	-0.31	0.18	0.62	0.1	0.6	-0.91	0.62	-0.01
Accounts Payable	-0.32	0.02	-0.4	-0.36	0.47	0.35	-0.26	-0.43	0.57	0.17	-0.69	0.46	0.02		-0.15	-0.28	0.42	-0.27	-0.05	-0.28	-0.38	0.26	-0.61	-0.18	-0.38	0.17
Cash	0.83	0.92	-0.19	-0.41	-0.25	0.44	-0.53	-0.38	0.14	-0.44	-0.27	0.21	-0.97	-0.15		-0.41	-0.3	0.96	0.28	-0.09	-0.43	-0.13	-0.44	0.97	-0.43	-0.01
Non Current Assets Total	0.09	-0.58	0.37	0.78	0.16	-0.47	0.79	0.62	-0.3	0.57	0.69	-0.62	0.54	-0.28	-0.41		0.61	-0.23	-0.47	0.19	0.76	0.45	0.74	-0.23	0.73	0.43
Non Currrent Assets Other	-0.02	-0.37	0.04	0.38	0.51	-0.17	0.46	0.16	0.25	0.58	-0.09	-0.18	0.32	0.42	-0.3	0.61		-0.24	-0.28	0.13	0.33	0.69	-0.01	-0.17	0.3	0.6
Cash And Short Term Investments	0.94	0.79	0.05	-0.15	-0.36	0.21	-0.28	-0.12	0.02	-0.26	-0.05	-0.06	-0.88	-0.27	0.96	-0.23	-0.24		0.23	0.03	-0.17	-0.16	-0.24	0.99	-0.17	-0.03
Common Stock Total Equity	0.09	0.27	0.13	-0.27	-0.44	-0.02	-0.28	-0.16	0.27	-0.13	-0.21	0.14	-0.31	-0.05	0.28	-0.47	-0.28	0.23		0.58	-0.25	-0.09	-0.29	0.21	-0.24	-0.15
Short Term Investments	0.09	-0.3	0.61	0.43	-0.37	-0.57	0.42	0.47	-0.05	0.39	0.32	-0.45	0.18	-0.28	-0.09	0.19	0.13	0.03	0.58		0.44	0.03	0.29	-0.05	0.44	-0.09
Non Current Liabilities Total	0.12	-0.73	0.84	1.0	-0.27	-0.86	0.97	0.98	-0.44	0.76	0.84	-0.95	0.62	-0.38	-0.43	0.76	0.33	-0.17	-0.25	0.44		0.0	0.82	-0.24	1.0	-0.01
Other Current Assets	-0.04	-0.1	-0.21	0.03	0.34	0.14	0.09	-0.14	0.36	0.21	-0.14	0.07	0.1	0.26	-0.13	0.45	0.69	-0.16	-0.09	0.03	0.0		-0.13	-0.08	-0.06	0.96
Property Plant And Equipment Gross	0.0	-0.63	0.6	0.8	-0.23	-0.68	0.78	0.8	-0.56	0.43	0.96	-0.72	0.6	-0.61	-0.44	0.74	-0.01	-0.24	-0.29	0.29	0.82	-0.13		-0.31	0.82	-0.14
Total Current Assets	0.93	0.82	-0.04	-0.21	-0.28	0.3	-0.33	-0.2	0.1	-0.27	-0.13	0.02	-0.91	-0.18	0.97	-0.23	-0.17	0.99	0.21	-0.05	-0.24	-0.08	-0.31		-0.24	0.05
Short Term Debt	0.11	-0.74	0.85	0.99	-0.28	-0.87	0.97	0.98	-0.44	0.76	0.83	-0.95	0.62	-0.38	-0.43	0.73	0.3	-0.17	-0.24	0.44	1.0	-0.06	0.82	-0.24		-0.07
Common Stock	0.09	0.02	-0.24	0.02	0.29	0.22	0.04	-0.15	0.22	0.09	-0.11	0.03	-0.01	0.17	-0.01	0.43	0.6	-0.03	-0.15	-0.09	-0.01	0.96	-0.14	0.05	-0.07

Click cells to compare fundamentals

Cyclacel Pharmaceuticals Account Relationship Matchups

Cyclacel Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	15.3M	36.8M	42.6M	27.5M	8.8M	8.4M
Total Stockholder Equity	11.7M	33.3M	37.3M	15.5M	607K	576.7K
Retained Earnings	(357.6M)	(366.1M)	(385.0M)	(406.2M)	(428.3M)	(406.9M)
Common Stock Shares Outstanding	54.4K	242.2K	595.1K	657.6K	850.8K	893.4K
Liabilities And Stockholders Equity	15.3M	36.8M	42.6M	27.5M	8.8M	8.4M
Other Stockholder Equity	370.1M	400.1M	423.0M	414.0M	429.8M	284.3M
Total Liab	3.6M	3.5M	5.3M	12.0M	8.2M	14.1M
Other Current Liab	1.5M	2.0M	3.2M	4.8M	4.6M	3.4M
Total Current Liabilities	2.4M	2.5M	5.3M	7.4M	8.2M	5.8M
Property Plant And Equipment Net	1.3M	1.3M	94K	174K	102K	96.9K
Net Debt	(10.7M)	(32.3M)	(36.5M)	(18.2M)	(3.3M)	(3.5M)
Accounts Payable	890K	514K	2.1M	2.6M	3.5M	2.2M
Cash	11.9M	33.4M	36.6M	18.3M	3.4M	3.2M
Non Current Assets Total	1.3M	1.3M	1.6M	3.1M	1.4M	1.7M
Non Currrent Assets Other	(1.3M)	(1.3M)	1.6M	2.9M	1.3M	1.3M
Cash And Short Term Investments	11.9M	33.4M	36.6M	18.3M	3.4M	3.2M
Non Current Liabilities Total	1.2M	1.1M	30K	4.6M	37K	35.2K
Other Current Assets	103K	66K	79K	6.1M	1.1M	1.0M
Property Plant And Equipment Gross	1.3M	1.3M	94K	174K	522K	839.0K
Total Current Assets	14.0M	35.5M	40.9M	24.4M	7.4M	7.1M
Accumulated Other Comprehensive Income	(819K)	(746K)	(748K)	(1.3M)	(908K)	(953.4K)
Common Stock	17K	6K	10K	4.5M	1K	950.0
Net Receivables	1.3M	1.3M	3.7M	5.6M	2.9M	2.9M
Inventory	703K	684K	577K	(5.6M)	(5.1M)	(4.8M)
Property Plant Equipment	27K	106K	94K	174K	156.6K	148.8K
Retained Earnings Total Equity	(342.5M)	(349.8M)	(357.6M)	(366.1M)	(329.5M)	(345.9M)
Net Tangible Assets	11.7M	33.3M	37.3M	15.5M	17.8M	23.9M
Capital Surpluse	365.1M	365.8M	370.1M	400.1M	460.1M	394.6M
Non Current Liabilities Other	124K	100K	1.2M	1.1M	1.2M	1.3M
Net Invested Capital	11.7M	33.3M	37.3M	20.0M	607K	576.7K
Net Working Capital	11.6M	33.0M	35.6M	17.0M	(717K)	(681.2K)
Capital Stock	17K	6K	10K	4.5M	1K	950.0

Pair Trading with Cyclacel Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclacel Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Cyclacel Stock

0.73	ACB	Aurora Cannabis Sell-off Trend	Pair Corr
0.73	CGC	Canopy Growth Corp Financial Report 27th of June 2024	Pair Corr
0.67	ELYM	Eliem Therapeutics Upward Rally	Pair Corr

The ability to find closely correlated positions to Cyclacel Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclacel Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclacel Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclacel Pharmaceuticals to buy it.

The correlation of Cyclacel Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclacel Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclacel Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Cyclacel Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:

How To Invest In Cyclacel

Details

Is Cyclacel Stock a good investment?

Details

What is Cyclacel Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.

Note that the Cyclacel Pharmaceuticals information on this page should be used as a complementary analysis to other Cyclacel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Cyclacel Stock analysis

When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine

Is Cyclacel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(26.75)

Revenue Per Share

0.494

Return On Assets

(0.86)

Return On Equity

(2.73)

The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cyclacel Total Current Assets vs Retained Earnings Analysis

Total Current Assets vs Retained Earnings

Total Current Assets vs Retained Earnings Correlation Analysis

Correlation Coefficient

Total Current Assets

Retained Earnings

Cyclacel Pharmaceuticals fundamental ratios Correlations

Cyclacel Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cyclacel Pharmaceuticals fundamental ratios Accounts

Pair Trading with Cyclacel Pharmaceuticals

Moving against Cyclacel Stock

Complementary Tools for Cyclacel Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Other Assets
Short Term Debt	+ 1.0	Non Current Liabilities Total
Short Term Debt	+ 0.99	Other Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Non Current Liabilities Total	+ 0.98	Short Long Term Debt Total
Short Term Debt	+ 0.98	Short Long Term Debt Total

Net Debt	- 0.98	Total Stockholder Equity
Cash	- 0.97	Net Debt
Current Deferred Revenue	- 0.97	Short Long Term Debt Total
Short Term Debt	- 0.95	Current Deferred Revenue
Non Current Liabilities Total	- 0.95	Current Deferred Revenue
Current Deferred Revenue	- 0.95	Other Assets